The physiology of glucagon-like peptide 1
In addition, weight loss medications are generally not prescribed for patients with eating disorders, and, therefore, patients should be screened for these conditions
Key takeaways include: Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
This ensures the medication our patients receive is exactly what it's supposed to besafe, pure, and effective
Patients should be counseled to seek immediate medical attention for severe, persistent abdominal pain radiating to the back, especially if accompanied by vomiting